Document is current
Any future updates will be listed below
-
Authors
Hahn, Andreas https://orcid.org/0000-0001-9727-7580
Reed, Murray B. https://orcid.org/0000-0002-4873-608X
Vraka, Chrysoula https://orcid.org/0000-0003-2065-6093
Godbersen, Godber M. https://orcid.org/0000-0002-9739-0724
Klug, Sebastian https://orcid.org/0000-0001-8714-6608
Komorowski, Arkadiusz https://orcid.org/0000-0002-1674-4333
Falb, Pia https://orcid.org/0000-0003-4817-3499
Nics, Lukas https://orcid.org/0000-0002-1034-876X
Traub-Weidinger, Tatjana https://orcid.org/0000-0003-1118-926X
Hacker, Marcus https://orcid.org/0000-0002-4222-4083
Lanzenberger, Rupert https://orcid.org/0000-0003-4641-9539
-
Funding
Funding for this research was provided by:
Austrian Science Fund (KLI 610, KLI 1006)
Vienna Science and Technology Fund (https://doi.org/10.47379/CS18039)
Österreichischen Akademie der Wissenschaften
Austrian Science Fund
- License Information
-
More Information
Article History
Received: 25 August 2023
Accepted: 22 November 2023
First Online: 6 December 2023
Declarations
:
: Participants were reimbursed and insured during the study. The study was approved by the ethics committee of the Medical University of Vienna (ethics numbers 1479/2015 and 2054/2020) and all procedures were carried out according to the Declaration of Helsinki.
: At the screening visit, all participants provided written informed consent after detailed explanation of the study protocol.
: RL received investigator-initiated research funding from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. M. Hacker received consulting fees and/or honoraria from Bayer Healthcare BMS, Eli Lilly, EZAG, GE Healthcare, Ipsen, ITM, Janssen, Roche, and Siemens Healthineers. All other authors report no conflict of interest in relation to this study.
